RISA Labs, a healthcare AI startup, has raised $11.1 million (over INR 100 crore) in a Series A funding round. The round was co-led by US-based venture capital firms Cencora Ventures and Optum Ventures.
Other investors in the round include Oncology Ventures, Z21 Ventures, and John Simon, cofounder of General Catalyst, through his Ventureforgood platform.
The company will use the new funds to expand its AI system to more cancer clinics, health systems, specialty pharmacies, and infusion centres across the United States.
“In our vision for oncology, there are two sides to every patient’s journey: getting them on the right therapy faster, and deepening our understanding of the disease for the next patient through data,” said Jaggi, CEO of RISA Labs.
“As oncology therapies increase in number and complexity, tools that streamline operations and enable faster access to treatment become vital,” said Jason Dinger, senior vice president at Cencora.
RISA Labs was founded in June 2024 by Kshitij Jaggi and Kumar Shivang and is based in Palo Alto. Its AI platform, called BOSS, helps simplify complex cancer care work by breaking it into smaller tasks that are handled by AI agents.
The system is specially built for cancer treatment and takes care of complicated insurance rules, multi-drug treatments, and disease-specific needs. RISA’s AI is designed to solve the major data and calculation challenges faced in modern cancer care.
The startup said that RISA is already live at some of the largest oncology practices in the US. In one such unit, approximately 80% of administrative staff time has been freed up, denial rates have been reduced by up to 40% and first-pass approval rates have reached 97.8%.
Looking ahead to 2026, the San Francisco-based startup plans to deepen its focus on oncology by partnering with ecosystem leaders to expand AI-driven workflows across the full continuum of cancer care.
Read More- IO River raises $20 million in Series A round led by S Capital
